(IDYA) Ideaya Biosciences - Overview
Stock: Kinase, Helicase, PARP, ADC, MAT2A, Targeted
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 50.6% |
| Relative Tail Risk | -1.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.75 |
| Alpha | 12.51 |
| Character TTM | |
|---|---|
| Beta | 1.002 |
| Beta Downside | 0.622 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.23% |
| CAGR/Max DD | 0.31 |
Description: IDYA Ideaya Biosciences January 13, 2026
Ideaya Biosciences (NASDAQ: IDYA) is a U.S.-based precision-medicine oncology company that builds its pipeline around molecular-diagnostic-selected patient cohorts. Its lead assets include IDE196 (PKC inhibitor for GNAQ/GNA11-mutant cancers) in a combined Phase 2/3 study, IDE397 (MAT2A inhibitor for MTAP-deleted solid tumors) in Phase 2, and several early-stage programs such as IDE849 (DLL3-ADC for SCLC) and IDE275 (WRN helicase inhibitor for MSI-high tumors). The firm also runs preclinical discovery platforms (DECIPHER CRISPR library, INQUIRE AI engine) and maintains research alliances with GSK, Pfizer, Gilead, Merck, and leading academic institutions.
As of the latest 10-Q (Q3 2024), Ideaya reported cash and cash equivalents of roughly $120 million, giving it an estimated 12-month runway at current burn rates (~$10-12 million per quarter). The companys market capitalization hovers around $550 million, reflecting a typical biotech discount for early-stage pipelines lacking FDA-approved products. Sector-wide, oncology biotech R&D spend grew ~8 % YoY in 2023, driven by increasing investor appetite for biomarker-driven therapies, while the average time from Phase 1 to market in oncology remains >7 years, underscoring the long-term risk profile of Ideaya’s candidates.
If you want a data-rich, quantitative view of how Ideaya’s risk-adjusted valuation stacks up against peers, consider checking ValueRay’s analyst platform for deeper insights.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -160.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 3.47 > 1.0 |
| NWC/Revenue: 343.6% < 20% (prev 22.7k%; Δ -22.4k% < -1%) |
| CFO/TA -0.09 > 3% & CFO -102.3m > Net Income -160.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (89.7m) vs 12m ago 4.06% < -2% |
| Gross Margin: 98.12% > 18% (prev -0.07%; Δ 9819 % > 0.5%) |
| Asset Turnover: 17.72% > 50% (prev 0.32%; Δ 17.40% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' -5.95
| A: 0.62 (Total Current Assets 802.7m - Total Current Liabilities 64.5m) / Total Assets 1.19b |
| B: -0.55 (Retained Earnings -653.3m / Total Assets 1.19b) |
| C: -0.13 (EBIT TTM -160.7m / Avg Total Assets 1.21b) |
| D: -6.99 (Book Value of Equity -651.2m / Total Liabilities 93.1m) |
| Altman-Z'' Score: -5.95 = D |
Beneish M 1.00
| DSRI: 0.00 (Receivables 3000 /20.0k, Revenue 214.8m/3.92m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.31 (AQ_t 0.30 / AQ_t-1 0.23) |
| SGI: 54.76 (Revenue 214.8m / 3.92m) |
| TATA: -0.05 (NI -160.7m - CFO -102.3m) / TA 1.19b) |
| Beneish M-Score: 34.83 (Cap -4..+1) = D |
What is the price of IDYA shares?
Over the past week, the price has changed by -0.06%, over one month by -11.40%, over three months by +7.77% and over the past year by +34.27%.
Is IDYA a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IDYA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.9 | 55.2% |
| Analysts Target Price | 49.9 | 55.2% |
| ValueRay Target Price | 37 | 15.1% |
IDYA Fundamental Data Overview January 31, 2026
P/S = 13.4621
P/B = 2.7006
Revenue TTM = 214.8m USD
EBIT TTM = -160.7m USD
EBITDA TTM = -156.7m USD
Long Term Debt = 27.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 328.0k USD (from shortTermDebt, last quarter)
Debt = 27.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -271.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.13b USD (2.89b + Debt 27.2m - CCE 786.9m)
Interest Coverage Ratio = unknown (Ebit TTM -160.7m / Interest Expense TTM 0.0)
EV/FCF = -20.23x (Enterprise Value 2.13b / FCF TTM -105.4m)
FCF Yield = -4.94% (FCF TTM -105.4m / Enterprise Value 2.13b)
FCF Margin = -49.06% (FCF TTM -105.4m / Revenue TTM 214.8m)
Net Margin = -74.82% (Net Income TTM -160.7m / Revenue TTM 214.8m)
Gross Margin = 98.12% ((Revenue TTM 214.8m - Cost of Revenue TTM 4.04m) / Revenue TTM)
Gross Margin QoQ = 99.50% (prev none%)
Tobins Q-Ratio = 1.80 (Enterprise Value 2.13b / Total Assets 1.19b)
Interest Expense / Debt = 92.01% (Interest Expense 25.1m / Debt 27.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -127.0m (EBIT -160.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.44 (Total Current Assets 802.7m / Total Current Liabilities 64.5m)
Debt / Equity = 0.02 (Debt 27.2m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = 1.73 (negative EBITDA) (Net Debt -271.7m / EBITDA -156.7m)
Debt / FCF = 2.58 (negative FCF - burning cash) (Net Debt -271.7m / FCF TTM -105.4m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.26% (Net Income -160.7m / Total Assets 1.19b)
RoE = -15.55% (Net Income TTM -160.7m / Total Stockholder Equity 1.03b)
RoCE = -15.15% (EBIT -160.7m / Capital Employed (Equity 1.03b + L.T.Debt 27.2m))
RoIC = -12.28% (negative operating profit) (NOPAT -127.0m / Invested Capital 1.03b)
WACC = 9.52% (E(2.89b)/V(2.92b) * Re(9.61%) + (debt cost/tax rate unavailable))
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.25%
Fair Price DCF = unknown (Cash Flow -105.4m)
EPS Correlation: 12.78 | EPS CAGR: 7.34% | SUE: 1.20 | # QB: 2
Revenue Correlation: -21.54 | Revenue CAGR: 210.6% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.93 | Chg30d=+0.007 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=-3.56 | Chg30d=-0.052 | Revisions Net=-2 | Growth EPS=-184.1% | Growth Revenue=-76.6%